Status:
TERMINATED
Study Evaluating Bifeprunox in Patients With Schizophrenia.
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Schizophrenia
Eligibility:
All Genders
18-66 years
Phase:
PHASE3
Brief Summary
An open-label extension study using a variable dose (20 to 30 mg daily) of bifeprunox to evaluate long-term safety.
Eligibility Criteria
Inclusion
- Outpatients who have successfully completed Wyeth study 3168A1-313.
- A signed and dated informed consent form for this study.
- No major protocol violations in the previous study.
Exclusion
- Clinically important abnormalities in the preceding short-term study that have not resolved.
- Use of prohibited treatments in the preceding short-term study.
- Meeting any exclusion criteria in the preceding short-term study
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2008
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00366327
Start Date
January 1 2007
End Date
March 1 2008
Last Update
February 11 2013
Active Locations (82)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock, Arkansas, United States, 72201
2
Little Rock, Arkansas, United States, 72211
3
Anaheim, California, United States, 92802
4
Anaheim, California, United States, 92804